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Abstract
Background: P-glycoprotein (P-gp) is an ATP-dependent membrane transporter that plays a pivotal role in eliminating
xenobiotics by active extrusion of xenobiotics from the cell. Multidrug resistance (MDR) is highly associated with the over-
expression of P-gp by cells, resulting in increased efflux of chemotherapeutical agents and reduction of intracellular drug
accumulation. It is of clinical importance to develop a P-gp inhibition predictive model in the process of drug discovery and
development.
Methodology/Principal Findings: An in silico model was derived to predict the inhibition of P-gp using the newly invented
pharmacophore ensemble/support vector machine (PhE/SVM) scheme based on the data compiled from the literature. The
predictions by the PhE/SVM model were found to be in good agreement with the observed values for those structurally
diverse molecules in the training set (n=31, r
2=0.89, q
2=0.86, RMSE=0.40, s=0.28), the test set (n=88, r
2=0.87,
RMSE=0.39, s=0.25) and the outlier set (n=11, r
2=0.96, RMSE=0.10, s=0.05). The generated PhE/SVM model also showed
high accuracy when subjected to those validation criteria generally adopted to gauge the predictivity of a theoretical
model.
Conclusions/Significance: This accurate, fast and robust PhE/SVM model that can take into account the promiscuous nature
of P-gp can be applied to predict the P-gp inhibition of structurally diverse compounds that otherwise cannot be done by
any other methods in a high-throughput fashion to facilitate drug discovery and development by designing drug
candidates with better metabolism profile.
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Introduction
P-glycoprotein (P-gp), which belongs to the ATP-binding
cassette (ABC) super family of transporters, utilizes the energy
that is released during the hydrolysis of ATP to actively translocate
a wide range of structurally unrelated compounds across the cell
membrane [1]. P-gp, which is encoded by human MDR1 (ABCB1)
gene and localized to chromosome 7q21, can be found in a variety
of normal human tissues, including liver, kidney, small and large
intestines, pancreas, brain, ovary and testes [2–4]. It is believed
that P-gp-mediated efflux plays an essential role in cellular
protection as well as in secretion and/or disposition by extruding
xenobiotics from mammalian cells [5]. For instance, it has been
found that oral absorption and central nervous system entry of
various drugs can be limited by the P-gp expression in
gastrointestinal tract (GIT) and brain capillary endothelial cells,
respectively [6]. As a result, P-gp exerts profound effects on the
absorption, distribution, metabolism, excretion and toxicity
(ADME/Tox) of an administrated drug [7].
In addition to expression in normal tissues, P-gp is also widely
expressed in many human cancers, causing multidrug resistance
(MDR), in which a given non-drug resistant cell or cell line becomes
cross-resistant to other diverse drugs after being treated by a single
drug. This will result in the reduction of intracellular drug
accumulation by active extrusion of drugs from the cell [5]. For
example, the efficacy of a variety of antitumor agents, such as
doxorubicin, paclitaxel, etoposideand vincristine,isdiminished once
the tumor cells overexpress P-gp [8]. Furthermore, there is a healthy
body of studies to support the fact that P-gp plays a critical role in
drug resistance in infectious diseases [9,10], brain diseases [11],
rheumatoid arthritis [12] and cancers [13], resulting in impairing
chemotherapeutic treatment. For instance, 17-allylamino-17-de-
methoxygeldanamycin (17-AAG) is the first-generation inhibitor of
molecular chaperone heat shock protein 90 (Hsp90), which has been
proposed tobea noveltherapeutictarget fora varietyof cancers[14]
because of its pivotal role in cancer progression and tumor survival
[14]. Nevertheless, the efficacy of 17-AAG is limited by its sensitivity
to MDR [15]. As such, novel Hsp90 inhibitors that can inhibit P-gp
are under clinical development [16–18]. Thus, MDR can increase
efflux of chemotherapeutical agents, reduce intracellular drug
accumulation, and create a supreme hurdle in the effective
chemotherapy of many disorders [19].
Inhibition of P-gp have broad and profound drug metabolism
and pharmacokinetics (DM/PK) implications [20] since it can
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bioavailability, resulting in adverse drug–drug interactions [21].
Thus, some MDR modulators may alter not only the concentra-
tion of chemotherapeutic agents in cells, but also their plasma
concentrations. For example, a clinical study unequivocally
demonstrated that the plasma concentration of orally administered
digoxin was dramatically reduced in combination with co-
administrated rifampin due to the P-gp mediated drug–drug
interactions [22]. Therefore, the inhibition of P-pg plays a
clinically important role in modern chemotherapy since it is
hoped to find specific P-gp modulators that can efficaciously
reverse MDR in resistant cell lines, restore sensitivity to
chemotherapy, and thus improve treatment results [23].
In silico approach has been proven to be a feasible and efficient
way to drug ADME/Tox assessments [24]. Of various modeling
techniques, pharmacophore modeling, which develops a predictive
model based on the combination of chemical features to mimic the
interactions between ligands and the target protein, is often
adopted [25]. In fact, numerous pharmacophore hypotheses have
been proposed to predict the P-gp inhibition [26–33]. Neverthe-
less, it is believed that P-gp is a highly flexible protein [34] as
manifested by the fact that it can interact with a broad range of
structurally and functionally diverse compounds [35,36]. The
highly promiscuous nature of P-gp that is a common characteristic
of membrane proteins [37] can be further illustrated by the
published crystal structures of the bacterial lipid transporter MsbA
[38] and homology models [39,40]. Furthermore, the mouse P-pg,
whose sequence shares 87% identity with human P-gp, is also
highly flexible as demonstrated by Figure 1, in which the crystal
structures [41], unbounded (PDB code: 3G5U) as well as co-
complexed with QZ59-RRR (PDB code: 3G60) and QZ59-SSS
(PDB code: 3G61), are superimposed. These proteins exhibit
significant structural discrepancies, especially the amino acid
residues Tyr
303, Phe
332, Phe
339, Phe
724, Leu
758, Phe
974 and
Tyr
949. In addition, promiscuity is not only the hallmark of P-gp
conformation but also its inhibitors since it has been observed that
P-gp can have multiple binding sites, viz. polyspecificity [42,43],
suggesting that inhibitors can interact with P-pg using different
chemical features.
Accordingly, no single predictive model will suffice to accurately
describe the interactions between this promiscuous protein and
those highly diverse inhibitors [27], otherwise the derived
predictive models can only be applied to some specific chemo-
types, which, in turn, will produce substantial prediction errors
once the test molecules are located outside the domain of those
chemotypes. This perplexing situation can be further illustrated by
the P-gp substrates, whose binding sites are blocked by most of
inhibitors [44] despite of the fact that substrates and inhibitors can
have different binding regions [45]. There is a growing consensus
in favor of using pharmacophore ensemble to model the
interactions between P-gp and substrates in order to take into
consideration its promiscuous nature [46,47], suggesting that it is
plausible to accurately model the interactions between P-gp and
inhibitors using pharmacophore ensemble.
Nevertheless, the promiscuous nature of P-gp and its inhibitors
can be resolved using a novel scheme recently derived by Leong
[48], in which a panel of plausible pharmacophore hypothesis
candidates were adopted to construct a pharmacophore ensemble
(PhE), which, in turn, was treated as input for regression analysis
via support vector machines (SVM) and the PhE/SVM scheme
can be illustrated by Figure 3 of Chen et al [49]. Unlike any other
analog-base modeling scheme, each pharmacophore member in
the PhE symbolizes a single protein conformation or a group of
spatially similar protein conformations. As such, the promiscuous
nature of target protein can be taken into consideration and,
practically importantly, it has been shown that the PhE/SVM
model executed better than the consensus prediction of multiple
pharmacophore models [48] Consequently, a number of systems,
whose target proteins are highly promiscuous, were also accurately
modeled, including the case studies of the liability of human ether-a ´-
go-go related gene (hERG) [48] as well as CYP2A6– [50] and
CYP2B6–substrate interactions [51]. Additionally, the developed
PhE/SVM model revealed a possible new protein conformation
that was never reported before in the investigation of CYP2A6–
substrate interactions [50], and it performed better than the
pharmacophore ensemble [48]. The aim of this investigation was
to develop an accurate, fast and robust in silico model based on the
PhE/SVM scheme to predict the binding affinity of P-gp
inhibitors. This shall facilitate drug discovery and development
by designing drug candidates with better metabolism profile.
Materials and Methods
Data compilation
To construct quality data for this investigation, comprehensive
literature search was carried out to retrieve EC50 values of 130
compounds, which were compiled from different source [28,52–
54], to maximize the structural diversity. In order to warrant a
better consistency, the average values were taken in case there
were two or more EC50 values in very close range for a given
inhibitor. Furthermore, all chemical structures were examined and
only those with definite stereochemistry were enrolled. All
molecules assembled in this investigation and references to the
literature are listed in Table S1 (Supporting Information).
Conformation search
The conformational flexibility of studied molecules was taken
into account by creating multiple conformers since three-
dimensional conformations of ligands are of critical importance
in developing pharmacophore models [55]. As such, all selected
molecules were subjected to conformation search to generate the
low-lying conformations, which were carried out using the mixed
Monte Carlo multiple minimum (MCMM) [56]/low mode [57] by
Figure 1. Superposed murine P-gp proteins. The superposition of
three murine P-gp proteins, whose PDB codes are 3G5U, 3G60 and
3G61 and color-coded by gray, green and maroon, respectively.
doi:10.1371/journal.pone.0033829.g001
Prediction of P-Glycoprotein Inhibition
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33829MacroModel (Schro ¨dinger, Portland, OR). MMFFs [58] was chosen
as force field and the truncated-Newton conjugated gradient
method (TNCG) was set as the energy minimization method.
Furthermore, the hydration effect and the solvation effect were
taken into consideration by using the GB/SA algorithm [59] and
water as solvent with a constant dielectric constant, respectively.
The number of selected unique structures was up to 255 with an
energy cutoff of 20 Kcal/mol (or 83.7 KJ/mol).
Sample partition
The chemical and biological characteristics of selected samples in
the training set play a pivotal role in determining the predictivity of
a generated pharmacophore hypothesis, which can be manifested
by the fact that different compound selections can produce different
pharmacophore models [60]. The critical factor to constructing a
perfect training set is to let HypoGen, which was the program
employed for automatic pharmacophore generation (vide infra),
‘‘learn’’ new knowledge from the input. For examples, structurally
similar compounds with significantly different biological activities or
structurally distinct compounds with similar biological activities are
expected to serve as perfect entries. Conversely, any redundancy in
the predictive models, viz. overfitting or overtraining, can be yielded
when structurally similar compounds with similar biological
activities are selected as the training set.
Ideally, an ideal training set should consist of at least 16
molecules to warrant its statistical significance, at least 4 orders of
magnitude in biological activity, approximately equal compounds
in each order of magnitude and novel information concerning
structure-activity relationship. More detailed selection criteria
have already been discussed elsewhere [61,62].
Thirty-one molecules, which totally consisted of 7142 confor-
mations, were deliberately selected from all collected molecules by
visually scrutinizing their chemical structures and activities to
constitute the training set for automatic pharmacophore genera-
tion and regression and their associated biological activities
spanned 7 orders of magnitude. The generated hypotheses were,
in turn, validated by those remaining eighty-eight molecules,
whose biological activities varied over 5 log units. In addition,
those molecules assayed by Labrie et al. [63] were deliberately
designated as the outlier set to assess the extrapolation capacity of
the developed model, viz. the level of robustness, since those
samples can mimic the real challenges to a predictive model in real
situation. Table S1 lists molecules selected for the training set, test
set and outlier set and their corresponding pEC50, respectively.
Pharmacophore generation
The HypoGen module in Discovery Studio (Accelrys, San Diego, CA)
was employed for automatic pharmacophore generation. It produces
and ranks the pharmacophore hypotheses, which quantitatively
correlate the three-dimensional arrangement of selected chemical
features mapped onto those molecules in the training set with the
corresponding activities through three phases, namely construction,
subtraction and optimization as compared with any other QSAR
techniques [64,65], which normally rely on regression to generate
predictive models. During the construction phase, HypoGen generates
common conformational alignment among those most active
molecules in the training set. The less useful pharmacophore
hypotheses such as common to most inactive molecules are
eliminated from the collection in the subtractive phase. The survived
pharmacophore hypotheses are further improved using the stimulat-
ed annealing scheme in the optimization phase. The theory and
principle of HypoGen have been describe in detail elsewhere [62].
Hydrogen bond donor (HBD), hydrogen bond acceptor (HBA)
and hydrophobic (HP) chemical features, which depict the
intermolecular interactions between an H atom on the ligand and
a highly electronegative atom such as an O, N or F atom on the
protein, between a highly electronegative atom on the ligand and an
H atom on the proteinand between nonpolarmoieties on both ligand
and protein, respectively, were chosen for pharmacophore hypothesis
development using different feature combination and minimum,
maximum and total numbers for each selected chemical feature as
well as total features. In addition, the chemical feature weights and
tolerances were varied in order to maximize the hypothesis diversity.
SVM calculations
Each single predicted pEC50 value by those pharmacophore
hypotheses in the PhE was fed as the input of SVM for further
regression. In other words, those predicted pEC50 values were treated
as descriptors for QSAR model development. As such, the
dimensionality of the SVM input space corresponds to the number
of pharmacophore models in the ensemble. Furthermore, the
regression calculations were carried out by the SVM package
LIBSVM (software available at http://www.csie.ntu.edu.tw/,cjlin/
libsvm)usingthe svm-trainmodule and the developed SVM models, in
turn, were validated by those compounds in the test set using the svm-
predict module. The runtime parameters, namely cost C,t h ew i d t ho f
the kernel function c and e and n in case of e-SVR and n-SVR
regression modes, respectively, were automatically scanned using an
in-house perl script by the systemic grid search algorithm [66].
Model validation
A number of statistical parameters, namely the correlation
coefficient (r
2) between the predicted and observed values,
standard deviation (s), root-mean-square error (RMSE), maximum
residual (DMax) and mean absolute error (MAE) were used to
evaluate the predictivity of a built model. A 10-fold cross-
validation scheme, yielding the cross-validation coefficient (q
2), was
also employed for internal validation.
All generated models were subjected to validations by those
criteria, which were initially proposed by Golbraikh et al. [67] and
adopted by Development of Environmental Modules for Evalu-
ation of Toxicity of pesticide Residues in Agriculture (DEME-
TRA) [68], shown as follows,
r2w0:6,
q2w0:5,
r2{r2
o
    
r2v0:1 and 0:85ƒkƒ1:15,
r2
o{r’
2
o
       v0:3
where r2
o and k are the correlation coefficient and slope of the
regression line (predicted vs. observed values) through the origin,
respectively, and r’
2
o is the correlation coefficient of the regression
line (observed vs. predicted values) through the origin.
Furthermore, the newly proposed modified version of r
2 [69],
which is defined as follows,
r2
m~r2 1{
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r2{r2
o
       
q   
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which should be large than 0.5 to be an acceptable model.
Results
PhE
Of all generated pharmacophore models using various selections
of chemical features and runtime parameters, three hypotheses,
denoted by Hypo A, Hypo B and Hypo C (listed in File S1), were
assembled to construct PhE based on their prediction performances
on every single molecule in the training set and test set as listed by
Table S1 and their corresponding statistical evaluations as listed by
Table 1. These three candidate models in the ensemble consist of a
variety of combinations of chemical features, namely one HBD and
four HPs in Hypo A; one HBA, one HBD and two HPs in Hypo B
and one HBD and three HPs in Hypo C.
In addition to various combinations of chemical features in
these three pharmacophore models, their spatial arrangements are
also different as exhibited by Figure 2. It can be found that one
HBD and two HPs are common features among them and the
closest distance between one HBD and one HP and that between
two HPs are 6.374 A ˚ and 8.716 A ˚ in Hypo A, respectively,
whereas the same measurements vary to 7.081 A ˚ and 10.365 A ˚ in
Hypo B as well as 6.506 A ˚ and 8.515 A ˚ in Hypo C, respectively.
The discrepancies among these three models can also be rendered
by the bond angle centered at one HP and connecting to one HBD
and another HP varies from 55.7u in Hypo A to 63.2u and 50.6u in
Hypo B and Hypo C, respectively. Figure 3 demonstrates the
superposition of these three models, and it can be observed that
these three models are different not only in absolute coordinates
but also in the relative relationships.
The three pharmacophore models, in general, predicted those
molecules in the training set well as asserted by their less significant
residuals (Table S1) and their corresponding statistical evaluations,
namely parameters RMSE, MAE and s (Table 1). In addition, all
of the correlation coefficients, viz. r
2 values, are larger than 0.80,
suggesting their statistical significance, which can be further
confirmed by inspecting the scatter plot of observed vs. predicted
pEC50 values as illustrated in Figure 4.
The maximum residuals in the training set generated by Hypo
A and Hypo B were resulted from the prediction of 17 with values
of 21.06 and 21.34, respectively, whose residual was only 20.76
by Hypo C. On the other hand, the prediction residuals of 50 were
only 20.15 and 20.58 by Hypo A and Hypo B respectively,
whereas Hypo C produced the maximum deviation of 21.00.
Conversely, 84 was perfectly predicted by Hypo A, Hypo B and
Hypo C with only residuals of 0.15, 0.00 and 0.13, respectively.
When applied to 89, Hypo A only yielded a residual of 20.15 and
Hypo B and Hypo C showed modest errors of 0.44 and 0.33,
respectively. Nevertheless, these three models adopted different
conformations to bind to P-gp as illustrated in parts A–C of
Figure 5, and this discrepancy becomes more pronounced by the
superposition of these three conformations as depicted in part D of
Figure 5, which clearly illustrates the need to construct a PhE to
address the variations in protein conformation.
These three hypotheses in the PhE, in general, also executed
well for those molecules in the test set as shown in Tables S1 and 1
and Figure 6, which displays the scatter plot of observed vs.
predicted pEC50 values for those molecules in the test set.
Therefore, it can be affirmed that Hypo A, Hypo B and Hypo C
are qualified to constitute PhE based on the their performances in
the training set and the test set as well as their statistical
evaluations as mentioned above despite the fact that modest
performance deteriorations from the training set to the test set can
be observed as suggested by all statistical parameters. The r
2 value
evaluated by Hypo A, for example, was lowered to 0.73 in the test
set, viz. a decrease of 0.12 from the training set. Similar
observations can also apply to Hypo B and Hypo C. Similar to
those observations found in the training set, prediction discrepan-
cies among these three pharmacophore models can also be found
in the test set. For instance, Hypo C produced the maximum error
from the prediction of 82 with an error of 1.58, whereas Hypo A
and Hypo B only yielded residuals of 0.07 and 0.67, respectively.
In fact, all of these three models showed various levels of
overtraining, albeit marginally, as depicted by their decreases in r
2
values and other parameters from the training set to the test set.
PhE/SVM
The final PhE/SVM model was generated by the SVM
regression of those three pharmacophore hypotheses in the
ensemble, yielding the number of the SVM input components
(dimensionality) three. The optimal parameters for running SVM,
which were selected based on the prediction results of those
samples in the training set and cross-validation as listed in Table
S1, are summarized in Table 2. It can be observed that the PhE/
SVM model executed better than all of those individual
hypotheses in the PhE for those molecules in the training set as
further demonstrated by the scatter plot of observed vs. the
predicted pEC50 values as shown in Figure 4, in which those points
obtained from the SVM model are generally closer to the
regression line than those obtained from the Hypo A, Hypo B and
Hypo C. As a result, the PhE/SVM yielded the largest r
2 and the
smallest RMSE, DMax, MAE and s among those four predictive
Table 1. Statistical evaluations, namely correlation coefficient
(r
2), RMSE, maximum residual (DMax), mean absolute error
(MAE), standard deviation of residual (s) and cross-validation
coefficient (q
2) in the training set, test set and outlier set
predicted by Hypo A, Hypo B, Hypo C and PhE/SVM.
Hypo A Hypo B Hypo C PhE/SVM
Training set
r
2 0.85 0.81 0.86 0.89
RMSE 0.46 0.52 0.45 0.40
DMax 1.06 1.34 1.00 0.97
MAE 0.35 0.40 0.36 0.29
s 0.30 0.34 0.29 0.28
q
2 N/A
{ N/A N/A 0.86
Test set
r
2 0.73 0.72 0.74 0.87
RMSE 0.58 0.57 0.52 0.39
DMax 1.49 1.39 1.58 1.01
MAE 0.38 0.40 0.36 0.30
s 0.43 0.41 0.38 0.25
Outlier set
r
2 0.79 0.70 0.84 0.96
RMSE 0.14 0.12 0.13 0.10
DMax 0.36 0.39 0.28 0.13
MAE 0.08 0.05 0.08 0.09
s 0.12 0.11 0.11 0.05
{Not applicable.
doi:10.1371/journal.pone.0033829.t001
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PhE/SVM model yielded residuals, which are smaller than the
maximal errors produced by those hypotheses in the PhE for most
of molecule in the training set and the smallest in some cases,
suggesting that the PhE/SVM model is the most accurate model.
The predictions of 2 by Hypo A, Hypo B, Hypo C and PhE/
SVM, for example, gave rise to residuals of 0.30, 0.48, 20.28 and
20.02, respectively.
When subjected to 10-fold cross-validation, the PhE/SVM
model yielded the correlation coefficient q
2 of 0.86, which only
decreased from the parameter r
2 by a value of 0.03, viz. a tiny
difference between both correlation coefficients. Thus, it can be
asserted that this PhE/SVM model exhibits highly statistical
significance between the predicted values and the input data and,
more importantly, it is highly possible that this SVM model is a
statistically authentic model.
When applied to those molecules in the test set, PhE/SVM only
shows negligible performance decreases from the training set as
compared with all models in the PhE, which can be depicted by
the parameters r
2, DMax and MAE (Table 1). The MAE value, for
instance, only raised from 0.29 in the training set to 0.30 in the test
set despite of the fact that the sample size in the latter was ca. 2-
fold more than that in the former. In fact, the parameters RMSE
and s indicate that PhE/SVM executed better in the test set than
in the training set. Thus, it can be assured that the PhE/SVM
model is a better predictor than any of pharmacophore models in
the ensemble for those molecules in the test set as shown by
Figure 6. Most importantly, those negligible differences between
both r
2 values and between r
2 and q
2 values as well as the small and
consistent RMSE values in both sets manifest the fact that PhE/
SVM is a well-trained predictive model since it will otherwise
produce at least one substantial difference in case of overtraining.
External validation
Eleven molecules, whose inhibition activities of P-gp were
investigated by Labrie et al. [63], were deliberately selected as the
outliers to further challenge the extrapolation power of generated
models since they are completely positioned outside the perimeter of
Figure 2. Pharmacophore models in the ensemble. Generated pharmacophore models (A) Hypo A, (B) Hypo B and (C) Hypo C, in which
hydrophobic, hydrogen-bond acceptor and hydrogen-bond donor features are represented by light blue blobs, magenta blobs and arrows, and
green blobs and arrows, respectively. The interfeature distances and angles among features, depicted in white, are measured in A ˚ngstroms and
degrees, respectively.
doi:10.1371/journal.pone.0033829.g002
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doi:10.1371/journal.pone.0033829.g003
Figure 4. Observed vs. predicted pEC50 values in the training set. Observed pEC50 vs. the pEC50 predicted by Hypo A, Hypo B, Hypo C and
SVM model for those molecules in the training set. The solid line, dashed lines and dotted lines correspond to the SVM regression of the data, 95%
confidence interval for the SVM regression and 95% confidence interval for the prediction, respectively.
doi:10.1371/journal.pone.0033829.g004
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principal components, which explain 88.6% of the variance in the
original data,asdemonstrated byFigure 7,suggesting thatthey serve
as a good metric for the robustness evaluation of a predictive model.
The prediction results of those molecules in the outlier set are
listed in Table S1 and their associated statistical evaluations are
summarized in Table 1. Hypo A, Hypo B and Hypo C yielded r
2
values of 0.79, 0.70 and 0.84, respectively, in the outlier set,
implying various performance decreases from the training set.
Conversely, RMSE, DMax, MAE and s indicated that the
performances of Hypo A, Hypo B and Hypo C increased from
the training set to the outlier set because of lowered values of those
parameters. However, this seemingly unusual characteristic for a
predictive model can be realized by the fact that, of 11 molecules
in the outlier set, the inhibition activities of 10 molecules are in the
same log unit, viz. very close activities.
Similar to the observations found in the training set and test set,
this PhE/SVM model performed better than any of pharmaco-
Figure 5. Superposition of pharmacophore models and 89. Pharmacophore models (A) Hypo A, (B) Hypo B and (C) Hypo C fitted to 89 and (E)
overlay of these three models, which are color-coded by red, blue and green, respectively. The chemical features are described in Figure 2.
doi:10.1371/journal.pone.0033829.g005
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those statistical parameters (Table 1) as well as the scatter plot of
observed vs. predicted pEC50 values (Figure 8). Furthermore, the
predictions by PhE/SVM are in extremely good agreement with
observed values for all of molecules in the outlier set as manifested
by the fact that the RMSE, DMax, MAE and s values are only 0.10,
0.13, 0.09 and 0.05, respectively, which are also smaller than their
counterparts in the training set. The parameter r
2 evaluated by
PhE/SVM even increased from 0.89 in the training set to 0.96 in
the outlier set. These statistical evaluations assert the fact that
PhE/SVM is completely insensitive to the outliers, suggesting that
it is a very robust predictive model as a result, which is of pivotal
importance to practical applications.
Predictive evaluations
The predictivity of generated PhE/SVM model was further
evaluated by those validation requirements proposed by Golbraikh
et al. [67] as well as Roy and Roy [69] in the training set, test set and
outlier set. The results, summarized in Table 3, indicate that PhE/
SVM not only yielded high statistical values but also met all
validation requirements, suggesting that this predictive model is
highly accurate and predictive. Furthermore, this PhE/SVM model
can maintain similar performances regardless in the training set, test
set and even outlier set as depicted by the little variations among
different data set. As a result, it is plausible to expect, based on the
facts mentioned above, that no substantial prediction errors will be
generated when applied to structurally novel compounds.
Discussion
It has been experimentally proven that P-gp has multiple binding
sites [71]. As a result, Ekins et al. produced four pharmacophore
hypotheses, which consisted of different combinations of chemical
features, based on different sets of samples [30]. More importantly,
the discrepancies in feature selections among these four models are
consistent with the fact that Hypo A, Hypo B and Hypo C in the
PhE also employed different chemical features, suggesting that
different chemotypes of inhibitors can interact with P-gp using
different chemical interactions, which completely agrees with the
observation of Pajeva et al. [29,32]. Thus, only a group of fixed
Figure 6. Observed vs. predicted pEC50 values in the test set. Observed pEC50 vs. the pEC50 predicted by Hypo A, Hypo B, Hypo C and SVM
model for those molecules in the test set. The solid line, dashed lines and dotted lines correspond to the SVM regression of the data, 95% confidence
interval for the SVM regression and 95% confidence interval for the prediction, respectively.
doi:10.1371/journal.pone.0033829.g006
Table 2. Optimal runtime parameters for the SVM Model.
Parameter Value
SVM type e-SVR
Kernel type Radial basis function
c 0.008
Cost 4
e 0.001
doi:10.1371/journal.pone.0033829.t002
Figure 7. Sample distribution in the chemical space. Molecular
distribution for those samples in the training set (filled circle), the test
set (open triangle) and the outlier set (gray square) in the chemical
space spanned by three principal components.
doi:10.1371/journal.pone.0033829.g007
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fully take into account the promiscuous nature of P-gp.
Furthermore, those four pharmacophore models developed by
Ekins et al. collectively consisted of HBD, HBA, HP and ring
aromatic (RA) as compared with PhE/SVM, which was
collectively composed of HBD, HBA and HP, indicating that
the only qualitative difference between those 4 models and PhE/
SVM is the absence of RA in the latter. Statistically, the lack of RA
does not deteriorate the performance of PhE/SVM as compared
with those four pharmacophore models. For instance, those four
predictive models generated the r
2 values of 0.77, 0.88, 0.86 and
0.76 in the training set, whereas PhE/SVM produced a value of
0.89, suggesting that the chemical feature RA is not a ncecssity to
develope a predictive model. As a result, it is plausible to replace
RA by HP, which can be manifested by the fact that the
pharmacophore model developed by Palmeira et al. [33], which
comprised one HBA and two RAs, predicted that the two RAs
fitted onto the aromatic rings of propafenone, which, in turn, were
depicted as hydrophobic by the predictive model proposed by
Pajeva and Wiese [29]. In fact, none of published predictive
inhibition models enrolled the chemcial feature RA except those
developed by Ekins et al. [30,31] and Palmeira et al. [33].
Furthermore, at least one HBA and one HP can always be
found among all published pharmacophore hypotheses for P-gp
inhibitors [26–29,31,32] except those models proposed by Ekins
et al. [30] and Palmeira et al. [33]. Collectively, PhE/SVM also
consisted of the chemical features HBA, HBD and HP.
Nevertheless, only Hypo B adopted the chemical feature HBA
among those three models in the PhE. This seemingly paradox can
be understood by the fact that one of predictive models developed
by Ekins et al. [30] did not employ the chemical feature HBA,
suggesting that not all inbitors interact with P-gp using HBA. In
other words, it is not necessary to always take into account HBA.
As a result, it is plausible to observe that not all of hypotheses in
the ensemble selected the chemical feature HBA.
Langer et al. developed a pharmacophore hypothesis, which was
composed of the chemical features (aromatic) HP, HBA and
positive ionizable (PI) [28]. Of 106 samples in the test set, whose
experimental values were no larger than 207 mM, 34 molecules
were projected as inactive since their predictive values were larger
than 3,100,000 mM. These substantial discrepancies between the
obseved values and predictions indicate their indiscriminations
against these samples that was plausibly due to the lack of some
key chemical features [28]. Conversely, the PhE/SVM model,
which was collectively comprised of the chemical features HBD,
HBA and HP, yielded residuals of no more than 1 log unit for
those same 34 molecules, asserting that PhE/SVM is a much more
accurate model and those important features were completely
taken into consideration. The most pronounced discrepancy
between both theoretical models are resulted from the prediction
of 24, which yielded residuals of 4.63 and 0.52 by the model
derived by Langer et al. and PhE/SVM, respectively. Thus, it is
presumable to attribute the qualitative differences between both
theoretical models to the fact that Langer et al. enlisted the
chemical feature PI without taking into account HBD, whereas
Figure 8. Observed vs. predicted pEC50 values in the outlier set. Observed pEC50 vs. the pEC50 predicted by Hypo A, Hypo B, Hypo C and SVM
model for those molecules in the outlier set. The solid line, dashed lines and dotted lines correspond to the SVM regression of the data, 95%
confidence interval for the SVM regression and 95% confidence interval for the prediction, respectively.
doi:10.1371/journal.pone.0033829.g008
Table 3. Validation verification based on prediction
performance of those molecules in the training set, test set
and outlier set.
Training set Test set
Outlier
set
n 31 88 11
r2
o 0.89 0.87 0.95
k 1.00 1.04 0.99
r2
m 0.89 0.87 0.86
r
2.0.6 x x x
q
2.0.5 x N/A
{ N/A
(r
22r2
o)/r
2,0.1 & 0.85#k#1.15 xx x
|r2
o2r’
2
o|,0.3 xx x
r2
m.0.5 xx x
{Not applicable.
doi:10.1371/journal.pone.0033829.t003
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role in inhibitor–P-gp interaction. The importance of HBD can be
further manifested by 13, for example, whose hydroxyl group can
be perfectly fitted to the chemical feature HBD in Hypo A, Hypo
B and Hypo C as illustrated by Figure 9.
In addition, numerous studies have demonstrated the impor-
tance of HBD in determining the interaction between inhibitor
and P-gp. For instance, Ekins et al. [30] and Pajeva et al. [29,32]
recruited the chemical feature HBD to develop their pharmaco-
phore hypotheses. Wang et al. [72], Zalloum and Taha [73] and
Chen et al. [74] employed HBD related descriptor to construct
their QSAR models; and even the CoMSIA model proposed by
Labrie et el. [75] also used the field HBD. Accordingly, it is
plausible to assume that the chemical feature HBD plays a critical
role in determining the interaction between inhibitor and P-gp.
Otherwise, any theoretical model may give rise to substantial
prediction errors for some molecules.
Conclusion
P-gp inhibition is vital for drug metabolism and pharmacoki-
netics profiling since it can lead to adverse drug-drug interactions
or even toxicity. A predictive model can be greatly valuable to
drug discovery and development. Nevertheless, any in silico model
that fails to take into account the promiscuous nature of P-gp
cannot accurately model the interactions between structurally
distinct inhibitors and P-pg. In this study, a quantitative predictive
model, derived from a novel scheme by assembling a panel of
pharmacophore hypothesis candidates to construct pharmaco-
phore ensemble, which takes into consideration protein plasticity,
and support vector machine, which generates a regression model,
was developed to predict the P-gp inhibition. This developed PhE/
SVM showed excellent prediction accuracy for those structurally
diverse 31 and 88 molecules in the training set and test set,
respectively, with excellent predictivity and statistical significance.
It also executed extremely well when applied to those molecules in
the outlier set, which were structurally dissimilar to those in the
training set, as compared with any other conventional pharma-
cophore models, which adopted fixed selections of chemical
features and can be only used to model molecules of specific
chemical structures, substantially limiting their applicability as a
result. Furthermore, the PhE/SVM model can elucidate the
discrepancies among all published pharmacophore models,
suggesting its superiority over the other theoretical models. Thus,
it can be asserted that this PhE/SVM model can be adopted as an
accurate and reliable predictive tool, even in the high throughput
fashion, to facilitate drug discovery and development by designing
Figure 9. Superposition of pharmacophore models and 13. Pharmacophore models (A) Hypo A, (B) Hypo B and (C) Hypo C fitted to 13. The
chemical features are described in Figure 2.
doi:10.1371/journal.pone.0033829.g009
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better absorption, higher bioavailability and more efficacy.
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